Imreg offering
Executive Summary
Firm seeks to raise $ 5 mil. through issuance of approximately 6.8 mil. units consisting of one share of common and one warrant for a share of common, according to recent filing with the Securities and Exchange Commission. Proceeds will be used to fund additional clinical trials of Imreg-1 and development of the firm's second immunomodulator, Imreg-2. FDA denied Imreg's request for a Treatment IND for Imreg-1 on April 28. Since that time, the firm has been negotiating with the agency over a second clinical trial. The company hopes to institute a treatment protocol with cost recovery while the second trial is ongoing.